-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Chengda Biotech (688739.SH) issued an announcement. Recently, the influenza virus lytic vaccine (high dose) developed by Chengda Biology (Benxi) Co., Ltd. (“Benxi subsidiary”), a wholly-owned subsidiary of the company, has obtained clinical trial approval from the State Drug Administration and completed all preparations for the phase I clinical trial, and officially entered the phase I clinical trial stage.

Zhitongcaijing·07/17/2026 08:49:05
Listen to the news
Zhitong Finance App News, Chengda Biotech (688739.SH) issued an announcement. Recently, the influenza virus lytic vaccine (high dose) developed by Chengda Biology (Benxi) Co., Ltd. (“Benxi subsidiary”), a wholly-owned subsidiary of the company, has obtained clinical trial approval from the State Drug Administration and completed all preparations for the phase I clinical trial, and officially entered the phase I clinical trial stage.